Laurent Pharmaceuticals Inc., a Montreal-based biopharma company, received approval from the FDA to start enrolling U.S. patients in RESOLUTION, a multicentric Phase II randomized placebo-controlled trial testing once-a-day oral LAU-7b as a potential treatment against COVID-19 disease. RESOLUTION will enroll approximately 200 hospitalized COVID-19 patients who will receive either LAU-7B or a placebo for a treatment duration of 14 days. LAU-7b, which showed potent antiviral effects in-vitro ag...